Coegin Pharma

3,74 SEK

-0,80 %

Mindre end 1K følgere

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-0,80 %

-8,11 %

-15,77 %

-22,08 %

-41,38 %

-11,58 %

-73,75 %

-88,24 %

-88,24 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Markedsværdi

106,93 mio. SEK

Aktieomsætning

29,6 t SEK

Omsætning

79 t

EBIT %

-25.888,61 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

21.5

2026

Delårsrapport Q1'26

21.5

2026

Generalforsamling '26

19.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse4.3.2026, 13.30

Coegin Pharma receives first purchase order for new scalp serum

Pressemeddelelse2.3.2026, 10.30

Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum

Selskabsmeddelelse26.2.2026, 13.30

Coegin Pharma AB (publ) publishes its year-end report for 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse19.2.2026, 17.40

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Pressemeddelelse2.1.2026, 08.30

Coegin Pharma provides an operational and strategic update

Pressemeddelelse22.12.2025, 12.30

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Pressemeddelelse19.12.2025, 08.25

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Pressemeddelelse12.12.2025, 10.50

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Selskabsmeddelelse27.11.2025, 08.45

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Selskabsmeddelelse20.11.2025, 13.50

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Pressemeddelelse14.11.2025, 13.42

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Pressemeddelelse6.11.2025, 13.45

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Selskabsmeddelelse17.10.2025, 15.05

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Pressemeddelelse13.10.2025, 08.02

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Selskabsmeddelelse17.9.2025, 12.30

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Selskabsmeddelelse10.9.2025, 13.00

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Selskabsmeddelelse21.8.2025, 12.30

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Pressemeddelelse20.8.2025, 06.30

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Selskabsmeddelelse12.8.2025, 12.45

Coegin Pharma changes language for company communication to English

Pressemeddelelse2.7.2025, 06.30

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.